



16 partners,  
including clinical hospitals and  
research laboratories from Europe,  
U.S. and Australia



If you are interested in participating in  
the EPISTOP project please contact:

**Sergiusz Józwiak**, Warsaw, Poland  
Project Coordinator  
sergiusz.jozwiak@gmail.com  
+48 22 815 78 54

**Anna Jansen**, Brussels, Belgium  
Dissemination Manager  
anna.jansen@vub.ac.be

**Paolo Curatolo**, Rome, Italy  
curatolo@uniroma2.it

**Rima Nabbout**, Paris, France  
rimanabbout@yahoo.com

**Pavel Krsek**, Prague, Czech Republic  
pavel.krsek@post.cz

**Bernhard Weschke**, Berlin, Germany  
bernhard.weschke@charite.de

**Floor Jansen**, Utrecht, the Netherlands  
f.e.jansen@umcutrecht.nl

**Martha Feucht**, Vienna, Austria  
martha.feucht@meduniwien.ac.at

**Lieven Lagae**, Leuven, Belgium  
lieven.lagae@uzleuven.be

**Kate Riney**, Brisbane, Australia  
kate.riney@health.qld.gov.au



**EPISTOP**  
Research project aimed  
at explaining the mechanisms  
of epileptogenesis  
We encourage physicians  
and parents of children with TSC  
to take part in the study

More info:

[www.EPISTOP.eu](http://www.EPISTOP.eu)



## **EPISTOP:**

- one of the largest international projects within the Health Theme of the 7th Framework Programme

- coordinated by 'The Children's Memorial Health Institute' in Warsaw, Poland

- engages 16 partners, including clinical hospitals and research laboratories from Europe, U.S. and Australia

The aim of EPISTOP is to examine the risk factors and biomarkers of epilepsy and to identify possible new therapeutic targets to block or otherwise modify the development of epilepsy (epileptogenesis) in humans. To achieve these objectives, epileptogenesis will be studied in two investigational settings: a prospective clinical study in infants with TSC and studies in epileptogenic brain tissue obtained from TSC patients. The project has started in November 2013 and will continue until October 2018.



### **Patients can contribute to the project by:**

- participating in the observational part of the study that includes clinical and neuropsychological assessments, video electroencephalography (video-EEG), brain magnetic resonance imaging (MRI) and blood sample analyses for genetic, protein, and immunological studies

- participating in the randomized part of the study, which aims at comparing the outcome of early (epileptiform EEG in the absence of clinical seizures) versus standard treatment (clinical seizures) in TSC

- providing their consent for studies on brain tissue samples collected during surgical interventions, if relevant

### **Patients eligible for enrolment:**

- fetuses and newborns with suspected TSC (the diagnosis of TSC will be confirmed prior to the enrolment in the study)
- newborns and infants up to the age of 4 months with diagnosed TSC (who have not developed epilepsy)

More info:  
**[www.EPISTOP.eu](http://www.EPISTOP.eu)**

